Management of newly diagnosed high ‐risk and intermediate‐risk follicular lymphoma with 90Y ibritumomab tiuxetan in a phase II study

Hematological Oncology, EarlyView.

Source: Hematological Oncology - April 30, 2018 Category: Hematology Authors: Neil L.Berinstein , Nancy M.Pennell , RashmiWeerasinghe , RenaBuckstein , EugeniaPiliotis , Kevin R.Imrie , LisaChodirker , Mary ‐AnneCussen , EllenMiles , Marciano D.Reis , ZeinaGhorab , Matthew C.Cheung Source Type: research